| Followers | 35 |
| Posts | 2237 |
| Boards Moderated | 0 |
| Alias Born | 10/18/2019 |
Monday, July 21, 2025 3:59:33 PM
Yes it is same doctor that presented dcvax -
: NYAS New York Academy of Science - DCVax® Phase 3 Final Results
“Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma”
Dr. Paul Mulholland, MBBS, MSc, PhD, FRCP
University College Hospital
This study is not related -
A clinical trial for patients newly diagnosed with glioblastoma, an aggressive form of brain cancer, has opened at the NIHR UCLH Clinical Research Facility based in the National Hospital for Neurology and Neurosurgery.
Led by consultant UCLH medical oncologist and UCL honorary associate professor Paul Mulholland, the UCL sponsored Win-Glio trial will recruit 16 patients over an 18-month period.
Patients will receive immunotherapy treatment using the drug ipilimumab, prior to the standard treatment when their immune system is at its strongest.
Following treatment in the trial, patients will go on to have the current standard treatment of surgery where appropriate, radiotherapy and chemotherapy and will receive ongoing monitoring by Dr Mulholland and his team.
This trial follows the NeAT-GLIO clinical trial led by Dr Mulholland and funded by the Jon Moulton Charity Trust that had to close due to lack of recruitment of patients. However, the one patient recruited to that trial is doing well with no active tumour present on scans more than two and half years on from treatment (see case study below).
: NYAS New York Academy of Science - DCVax® Phase 3 Final Results
“Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma”
Dr. Paul Mulholland, MBBS, MSc, PhD, FRCP
University College Hospital
This study is not related -
A clinical trial for patients newly diagnosed with glioblastoma, an aggressive form of brain cancer, has opened at the NIHR UCLH Clinical Research Facility based in the National Hospital for Neurology and Neurosurgery.
Led by consultant UCLH medical oncologist and UCL honorary associate professor Paul Mulholland, the UCL sponsored Win-Glio trial will recruit 16 patients over an 18-month period.
Patients will receive immunotherapy treatment using the drug ipilimumab, prior to the standard treatment when their immune system is at its strongest.
Following treatment in the trial, patients will go on to have the current standard treatment of surgery where appropriate, radiotherapy and chemotherapy and will receive ongoing monitoring by Dr Mulholland and his team.
This trial follows the NeAT-GLIO clinical trial led by Dr Mulholland and funded by the Jon Moulton Charity Trust that had to close due to lack of recruitment of patients. However, the one patient recruited to that trial is doing well with no active tumour present on scans more than two and half years on from treatment (see case study below).
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
